A Phase 1/2 interventional study of Soy-tomato juice product and Will include a soy-tomato juice product to be consumed during the 4 week intervention phase. A total of about 12 ounces (administered in two small cans) of the juice will be consumed in Recurrent Acute Pancreatitis and Chronic Pancreatitis, sponsored by Ohio State University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by Ohio State University · Phase 1/2, Interventional, and Treatment
This goal of this clinical trial is to see if people with recurrent acute pancreatitis or chronic pancreatitis can tolerate and regularly drink a tomato juice beverage. Researchers will also measure inflammation and ask participants to report how they feel. Everyone in the study will receive the tomato juice drink, and both participants and researchers will know what is being taken. The investigators expect the drink will be well tolerated, may lower inflammation, and may improve participant-reported symptoms and quality of life.
This is a pilot, single arm, open label clinical trial to assess the tolerability and compliance of a soy-tomato juice dietary intervention in participants with recurrent acute pancreatitis (RAP) / chronic pancreatitis (CP) and evaluate the effects of the diet on inflammation and patient-reported outcomes (PROs). The investigators hypothesize this diet will be well tolerated, reduce measures of systemic inflammation, and potentially improve PROs.
During the trial, participants will complete a 4-week run-in phase where they are asked to consume a modified diet low in soy and lycopene. Then, participants will be provided a soy-tomato juice product to be consumed during the 4-week intervention phase. A total of about 12 ounces (administered in two small cans) of the juice will be consumed daily.
752 studies on the registry are indexed under Pancreatitis; 181 are open to participants now.
This study's planned enrollment of 35 is below the median of 80 across 448 interventional studies indexed under Pancreatitis.
Browse Pancreatitis studies →Ohio State University is the lead sponsor of 640 studies on the registry; 144 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 45 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
4 week run-in phase where they are asked to consume a diet low in soy and lycopene, then they will receive the intervention for 4 weeks.
Dietary Supplement: Soy-tomato juice product · Dietary Supplement: Will include a soy-tomato juice product to be consumed during the 4 week intervention phase. A total of about 12 ounces (administered in two small cans) of the juice will be consumed
A high lycopene tomato (with levels 2-3x higher than typical) will be grown at OSU farms, as we have done previously. Tomatoes will be harvested and transported to OSU's Food Industries Center (Columbus, OH) for processing into juice and canned using commercial methods. A soy isoflavone extract will be acquired from a commercial supplier, tested for isoflavone content, and dosed into the juice before canning. Our juice recipe has been formulated and previously tested to ensure palatability. Proximate analysis (i.e., the information found on a nutrition facts panel) will be collected from our final juice, along with carotenoid and soy isoflavone levels to fully characterize our intervention agent.
This is a novel dietary supplement.
Safety of the Dietary Intervention
Safety will be evaluated by monitoring adverse events throughout the study. Information will be collected through routine study assessments, including participant interactions, diary entries, vital signs, and standard clinical laboratory testing. Adverse events will be graded using the Common Terminology Criteria for Adverse Events (CTCAE v.5.0). For this study, we define a dose-limiting toxicity (DLT) as the appearance of any adverse event reaching Grade 3-5 toxicity or that otherwise prevents continuation of the intervention. Adverse events will be graded using established clinical criteria, and the number and severity of events observed during the intervention period will be summarized to determine the rate of dose-limiting toxicities
Time frame: From enrollment to the end of treatment at 8 weeks
Assessment of Compliance With the Dietary Intervention (soy)
Participant adherence to the dietary intervention will be monitored using daily self-report diaries, where individuals record how much of the study beverage they consumed each day. These entries will be used to assess overall adherence across the intervention period without disclosing any specific targets or thresholds to participants. In addition to self-reports, the study will also evaluate biological markers of dietary intake. Levels of compounds derived from the soy components of the beverage (isoflavone metabolites)) will be measured in urine collected before and after the intervention.
Time frame: From enrollment to the end of treatment at 8 weeks
Assessment of Compliance With the Dietary Intervention (lycopene)
Description: In addition to self-reports and assessment of soy metabolites, investigators will also evaluate biological markers of dietary intake. Levels of compounds derived from the lycopene components of the beverage will be measured in plasma collected before and after the intervention.
Time frame: From enrollment to the end of treatment at 8 weeks
Determine the Change in Inflammatory Marker Levels
Changes in circulating inflammatory markers will be evaluated before and after the dietary intervention. Concentrations (pg/mL) of key markers (Interleukin-5, Interleukin-1beta, Tumor Necrosis Factor-alpha) will be measured using standard laboratory techniques to characterize overall shifts in inflammation-related signaling. The analysis will help determine whether the intervention is associated with measurable changes in the body's inflammatory profile over time.
Time frame: From enrollment to the end of treatment at 8 weeks
Determine the Change in Physical Activity Levels
Physical activity will be evaluated at two points during the study using a validated wearable activity monitor. The amount of daily activity, expressed in minutes, will be analyzed as a continuous measure. This assessment provides an estimate of both sedentary behavior and ambulatory movement in real-world settings, allowing us to characterize overall patterns of physical activity during the trial.
Time frame: From enrollment to the end of treatment at 8 weeks
Determine the Change in Average Abdominal Pain Score
Changes in abdominal pain will be evaluated throughout the study. Pain intensity will be measured at each study visit and through daily participant diaries using the standard numeric rating scale (range of 0-10; higher value represents higher pain intensity). This approach provides a simple, widely used quantitative measure of abdominal discomfort, allowing us to track overall patterns of pain over the course of the trial
Time frame: From enrollment to the end of treatment at 8 weeks
Determine the Change in Quality of Life
Quality of life will be assessed at multiple time points using a validated questionnaire specific to pancreatitis (Pancreatitis Quality of Life, PANQOLI). Overall scores on this scale range from 0 to 103, with higher scores indicating a better quality of life. Changes from baseline in the overall composite score will be evaluated to understand how participants' quality-of-life experiences shift over the course of the study.
Time frame: From enrollment to the end of treatment at 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ohio State University